Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Liangliang Ren(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Xin Li, Xinhua Wang(Zhengzhou University), Lei Zhang(First Affiliated Hospital of Zhengzhou University), Jingjing Wu(Beijing Tian Tan Hospital), Jiaqin Yan(First Affiliated Hospital of Zhengzhou University), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Fei Kong(Shanghai Jiao Tong University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Yu Chang(Jilin University), Feifei Nan(First Affiliated Hospital of Zhengzhou University), Xiaoyan Feng(Academy of Military Medical Sciences), Ling Li(First Affiliated Hospital of Zhengzhou University), Zhi‐Yuan Zhou(Tsinghua University)
Cited by 7
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer
|Cancer Cell|2018|251
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
|The Lancet Infectious Diseases|2015|231
Altermagnets as a new class of functional materials
|Nature Reviews Materials|2025|200